Search Results
Your search for ,WHo matches 20700 pages
Showing 15001 - 15050Detection of Thyroid Cancer Most Cost-Effective With Physical Examination, Not Ultrasound Screening
A study evaluating annual physical examination as a screening method to detect thyroid cancer in cancer survivors exposed to neck radiation has shown a substantial cost reduction compared with ultrasound screening, with no thyroid cancer–related mortality.1 According to the analysis, this method...
Three Industry Leaders Join the CancerLinQ Team
CancerLinQ LLC, a wholly owned nonprofit subsidiary of ASCO, has named three new members to its leadership team. David Dornstreich, Robert Merold, and Jennifer L. Wong recently joined CancerLinQ LLC and, in their various roles, will be utilizing their extensive strategic experience to fully realize ...
Cultural Awareness and Sensitivity Among Oncology Surgeons Do Not Necessarily Result in Culturally Competent Care
A survey of oncology surgeons from six hospitals in Washington State found that the surgeons in the sample “displayed and valued cultural awareness and sensitivity” but that “cultural awareness and sensitivity did not necessarily result in culturally competent behavior.”...
Carboplatin/Paclitaxel Tops Oxaliplatin/Capecitabine as Neoadjuvant Regimen for Esophageal Cancer
The United Kingdom’s phase II NEOSCOPE trial compared the toxicity and efficacy of two preoperative chemoradiation regimens—carboplatin/paclitaxel and oxaliplatin/capecitabine—and judged one to be the winner. “CarPacRT passed the prespecified efficacy criteria for taking forward to phase III, but...
2016 Head and Neck Cancer Symposium: Study Maps Distinct Molecular Signatures of HPV-Positive Throat Cancer by Smoking Status
Patients with throat cancer exposed to both human papillomavirus (HPV) and tobacco smoke demonstrate a pattern of mutations along several key cancer genes, according to research presented by Zevallos et al at the 2016 Multidisciplinary Head and Neck Cancer Symposium (Abstract 1). These distinct...
Expert Point of View: Claus Rödel, MD
Claus Rödel, MD, Director and Chair of the Department of Radiotherapy and Oncology, University of Frankfurt, Germany, and invited discussant of the study, pointed out that these investigators found “the opposite” of what most previous studies have shown: Others have found an increased risk for...
Radiotherapy for Rectal Cancer: Study Reports No Risk for Subsequent Pelvic Tumors
Second malignancies were not more common among patients who underwent radiotherapy for rectal cancer. In fact, radiotherapy appeared to offer some degree of protection against subsequent cancers, according to the findings of a study from the Netherlands reported at the 2016 Gastrointestinal Cancers ...
Serum Tumor Marker Testing Overused, Especially for Solid Tumors
A retrospective review to evaluate the frequency of serum tumor marker testing “found a high rate of serum tumor marker testing overuse and extreme overuse in patients with advanced solid tumors,” Melissa K. Accordino, MD, of Columbia University College of Physicians and Surgeons, New...
Shorter Radiation Course May Benefit Patients With Locally Advanced Rectal Cancer
As neoadjuvant treatment for locally advanced rectal cancer, a shorter course of radiation therapy followed by chemotherapy may be as good as, or better than, standard chemoradiotherapy, according to a study from the Polish Colorectal Study Group presented at the 2016 Gastrointestinal Cancers...
Expert Point of View: Bertram Wiedenmann, MD, PhD and Markus Moehler, MD, PhD
Commenting on the programmed cell death protein 1 (PD-1)/PD-1 ligand (PD-L1) antibodies in tumors with mismatch repair deficiency, Bertram Wiedenmann, MD, PhD, Professor of Internal Medicine and Gastroenterology, Universitätsmedizin Berlin, Germany, suggested, “The efficacy of pembrolizumab...
Receipt of Adjuvant Therapy at High-Volume Center Improves Survival in Patients With Pancreatic Cancer
Patients with pancreatic cancer who received adjuvant chemotherapy at a high-volume center had superior median and 5-year overall survival than did patients who were treated in a community setting, according to the results of a study presented at the 2016 Gastrointestinal Cancers Symposium.1 This...
Cost in the Context of Value for Cancer Medicines
Bringing new cancer therapies through the discovery and development process entails considerable risk and many years of study. It also requires substantial investment and incentives from the public and private sectors to fuel future investment and discovery. A system that rewards advances in cancer ...
Antithymocyte Globulin Reduces Need for Immunosuppressants After Hematopoietic Cell Transplantation From Unrelated Donors
In a phase III trial reported in The Lancet Oncology, Walker et al found that treatment with antithymocyte globulin reduced the need for immunosuppressive therapy in patients with hematologic malignancies receiving hematopoietic cell transplantation from unrelated donors. Study Details In this...
Inherited Genetic Variations That Lead to Severe Drug Toxicity in Pediatric Leukemia Discovered
An international research team has determined how inherited gene variations lead to severe drug toxicity that may threaten chances for a cure in children with leukemia. St. Jude Children’s Research Hospital scientists led the study, results of which set the stage to expand the use of a...
Anti–PD-1/PD-L1 Antibodies Make Strong Showing in Gastrointestinal Cancers
Although the results may not yet be as impressive as those seen in melanoma, lung, and kidney cancers, monoclonal antibodies targeting the programmed cell death protein 1 (PD-1) are producing responses, with some durability, in gastrointestinal cancers, according to studies presented at the 2016...
Fecal Immunochemical Test Sensitive and Effective for Annual Colorectal Cancer Screening
Annual screening with the fecal immunochemical test is highly sensitive for detecting colorectal cancer and “is feasible and effective for population-level colorectal cancer screening,” according to a large-scale retrospective cohort study assessing the fecal immunochemical...
Updated Guidelines Recommend That Patients With Colorectal Cancer Undergo Colonoscopy After Cancer Resection
According to new recommendations from the U.S. Multi-Society Task Force on Colorectal Cancer published by Kahi et al in Gastroenterology, postoperative colonoscopy is associated with improved overall survival for colorectal cancer patients. Therefore, it is critically important that colorectal...
Norwegian Male Cancer Survivors Less Likely to Reproduce
A study of all Norwegian men born between 1965 and 1985 showed that male cancer survivors are less likely to have children than those without a cancer diagnosis. “These findings are important for male cancer survivors, seeing as we can identify groups at risk of having reproduction...
Increased Risk of Severe Neurocognitive Impairment in Adult Survivors of Pediatric CNS Tumors
As reported in the Journal of Clinical Oncology by Brinkman et al, a study in the St. Jude Lifetime Cohort showed that adult survivors of pediatric central nervous system (CNS) tumors are at increased risk of severe neurocognitive impairment. Study Details The study involved 224 survivors of CNS...
Eribulin Improves Overall Survival vs Dacarbazine in Advanced Liposarcoma or Leiomyosarcoma
In a phase III trial reported in The Lancet, Schöffski et al found that eribulin improved overall survival vs dacarbazine in patients with advanced or metastatic soft-tissue sarcoma who had received at least two prior systemic treatments for advanced disease. Outcome in the subgroup with...
High Conditional Survival for Patients With Metastatic Testicular Germ Cell Tumors Receiving First-Line Curative Therapy
Two-year conditional overall and disease-free survival were substantially increased in patients surviving and surviving without recurrence for 2 years after first-line curative therapy for metastatic testicular germ cell tumors, according to a study reported by Ko et al in the Journal of Clinical...
Dutch Study Shows Increased Risk of Second Cancer for Survivors of Hodgkin Lymphoma During Long-Term Follow-up
In a Dutch study reported in The New England Journal of Medicine, Schaapveld et al found that survivors of Hodgkin lymphoma treated between 1965 and 2000 were at a 4.6-fold greater risk of second cancer vs the general population during long-term follow-up. There was no significant difference in the ...
Younger T Cells May Improve Immunotherapy for Pediatric Cancer
Pediatric oncologists from The Children’s Hospital of Philadelphia (CHOP) have investigated techniques to improve and broaden a novel personalized cell therapy to treat children with cancer. The researchers say that a patient’s outcome may be improved if clinicians select specific...
Interruption of Radiation Therapy Due to Noncompliance Risks Cancer Recurrence
Cancer patients who miss two or more radiation therapy sessions (except for planned treatment breaks) have a worse outcome than fully compliant patients, investigators at Montefiore Einstein Center for Cancer Care (MECCC) and Albert Einstein College of Medicine's Albert Einstein Cancer Center have...
ACS/ASCO Breast Cancer Survivorship Care Guideline
The American Cancer Society (ACS) and ASCO have issued a Breast Cancer Survivorship Care guideline, published jointly in the Journal of Clinical Oncology and CA: A Cancer Journal for Clinicians. The guideline recommendations were formulated by a multidisciplinary expert work group and are based on...
Preclinical Device Hits Pancreatic Tumors With Drug Cocktail, Sparing the Body
A highly lethal cancer sometimes requires large doses of highly toxic drugs. However, a blitzkrieg approach can be unfeasible for some patients due to severe side effects. Now a team of researchers at the University of North Carolina at Chapel Hill has found that an implantable device can deliver a ...
Study Finds Time Lag Between Positive Fecal Blood Test and Follow-up Colonoscopy
Annual testing for blood in the stool using high-sensitivity guaiac fecal occult blood tests or fecal immunochemical tests is one of several recommended colorectal cancer screening strategies for adults 50 to 70 years old. However, although a positive finding requires a follow-up colonoscopy to...
Reduction in Late Mortality in Childhood Cancer Survivors in the Childhood Cancer Survivor Study Cohort
In a study reported in The New England Journal of Medicine, Armstrong et al found that late mortality decreased over time among 5-year survivors of childhood cancer in the Childhood Cancer Survivor Study cohort. The reduction is consistent with efforts during recent decades to modify treatment with ...
Possible Marker for Recurring HPV-Linked Oropharyngeal Cancers
A retrospective analysis of human papillomavirus (HPV) antibodies in patients treated for oropharyngeal cancers linked to HPV infection suggests at least one of the antibodies could be useful in identifying those at risk for a recurrence of the cancer, said scientists at The Johns Hopkins...
ASCO Issues Policy Statement Calling for Improvements to Clinical Pathway Programs in Oncology
ASCO released a new policy statement with recommendations to ensure that clinical pathways in oncology promote—not hinder—the care of patients with cancer. Published by Zon et al in the Journal of Oncology Practice,1 the statement asserted that the way in which these treatment management tools in...
Alectinib in ALK-Positive Metastatic NSCLC After Crizotinib
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On December 11, 2015, alectinib (Alecensa) was granted...
Richard ‘Buz’ Cooper, MD, Noted Health Policy Expert, Dies at 79
Addressing disparities of cancer care that result in poorer outcomes among certain populations remains a persistent challenge in the oncology community and in the health-care system at large. It is, to a large degree, a medical story of haves and have-nots. Richard “Buz” Cooper, MD, a preeminent...
The Sohn Conference Foundation Unveils The Sohn Precision Medicine Program at Columbia University Medical Center
The Sohn Conference Foundation unveiled The Sohn Precision Medicine Program at Columbia University Medical Center (CUMC) on January 14, 2016. Funded by a $1.5 million grant provided by The Sohn Conference Foundation over approximately a 3-year period, the Program will provide high-risk pediatric...
Immunotherapy Expert Crystal Mackall, MD, Joins Stanford Medicine Faculty
Cancer immunotherapy expert Crystal Mackall, MD, joined the Stanford University School of Medicine faculty on January 1 as Professor of Pediatrics and Medicine, as well as Associate Director of the Stanford Cancer Institute and Co-Medical Director of the Stanford Laboratory for Cell and Gene...
Patricia A. Ganz, MD, Awarded Joseph V. Simone Award and Lecture for Excellence in Quality and Safety in the Care of Patients With Cancer
ASCO will honor Patricia A. Ganz, MD, an accomplished medical oncologist and renowned advocate for improving the quality of cancer care from prevention through survivorship, with its first annual Joseph V. Simone Award and Lecture for Excellence in Quality and Safety in the Care of Patients With...
Certainty
The following essay by William N. Harwin, MD, is adapted from The Big Casino: America’s Best Cancer Doctors Share Their Most Powerful Stories, which was coedited by Stan Winokur, MD, and Vincent Coppola and published in May 2014. The book is available on Amazon.com and thebigcasino.org. My wife...
James K.V. Willson, MD, Named Chief Scientific Officer of CPRIT
James K.V. Willson, MD, Associate Dean of Oncology Programs and Professor and Director of the Harold C. Simmons Comprehensive Cancer Center at University of Texas (UT) Southwestern Medical Center, has been named Chief Scientific Officer of the Cancer Prevention and Research Institute of Texas...
New AJCC Precision Medicine Guidelines Aimed at Improving Personalized Cancer Treatment Plans for Patients
A committee of national experts, led by a Cleveland Clinic researcher, has established first-of-its-kind guidelines to promote more accurate and individualized cancer predictions, guiding more precise treatment and leading to improved patient survival rates and outcomes. These guidelines were...
Selected Abstracts From 2015 ASH Annual Meeting: Part 2
Here are several more abstracts selected from the proceedings of the 2015 American Society of Hematology (ASH) Annual Meeting and Exposition, highlighting therapeutics in acute leukemias and myelodysplastic syndromes. For five other top abstracts on therapies for acute leukemias and myelodysplastic ...
Expanded Approval of Pembrolizumab in Unresectable or Metastatic Melanoma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On December 18, 2015, approval of the programmed cell death...
A Famous French Oncologist’s Gastronomic Advice for Reducing Cancer Risk
BookmarkTitle: The Anti-cancer Diet: Reduce Cancer Risk Through the Foods You EatAuthors: David Khayat, MDPublisher: W.W. Norton & CompanyPublication date: April 2015Price: $26.95; hardcover, 288 pages In 2002, David Khayat, MD, was in Turkey on holiday with friends when he received a call...
Fear’s Many Deleterious Consequences
Bookmark Title: The Fear Cure: Cultivating Courage as Medicine for the Body, Mind, and Soul Author: Lissa Rankin, MD Publisher: Hay House, Inc Publication date: February 23, 2015 Price: $25.99; hardcover, 336 pages Fear is a healthy survival mechanism, a fight-or-flight response designed to put...
A Pioneering Oncologist’s Roadmap Forward
Bookmark Title: The Death of Cancer: After Fifty Years on the Front Lines of Medicine, a Pioneering Oncologist Reveals Why the War on Cancer Is Winnable—and How We Can Get There Authors: Vincent T. DeVita, Jr, MD, and Elizabeth DeVita-Raeburn Publisher: Farrar, Straus and Giroux Publication date:...
FDA Approves Ofatumumab for Patients With Chronic Lymphocytic Leukemia in Complete or Partial Response
The U.S. Food and Drug Administration (FDA) has approved ofatumumab (Arzerra), a CD20-directed cytolytic monoclonal antibody, for extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive chronic lymphocytic leukemia...
Looking at the Real-World Effects of Genetic Testing
According to the most recent estimates, 55% to 65% of women who inherit the BRCA1 mutation and about 45% of women who inherit the BRCA2 mutation will develop breast cancer by the time they are 70 years old. There is also a substantial increase in the probability of developing ovarian cancers in...
Defibrotide Under Review for Transplant-Related Complication
A potentially fatal complication of hematopoietic stem cell transplantation may be reversed with the use of a novel drug currently under priority review at the U.S. Food and Drug Administration (FDA). Hepatic veno-occlusive disease/sinusoidal obstruction syndrome is usually a serious complication...
How Cancer and Its Treatments Affect Cognitive Function
Although chemotherapy is often cited as the main culprit for diminishing cognitive function in patients with cancer, ushering the term “chemobrain” into the vernacular, research by Tim A. Ahles, PhD, and his colleagues is showing that multiple factors may contribute to the condition.1 Using breast...
Increased Incidence of in Situ and Invasive Melanoma in Denmark
In a study reported in JAMA Dermatology,1 Neel Maria Helvind, MD, of the University Hospital Rigshospitalet, Copenhagen, Denmark, and colleagues analyzed the increases in melanoma incidence seen in Denmark between 1985 and 2012. Over that time, the incidence of malignant melanoma doubled to rates...
Transcription Factor CDX2 May Be Prognostic Biomarker in Stage II and III Colon Cancer
In a study reported in The New England Journal of Medicine, Dalerba et al found that absence of the transcription factor CDX2, although prognostic for poor outcome in stage II and III colon cancer vs cancers with CDX2 expression, identified a subgroup of high-risk patients who appeared to benefit...
Increased Survival and Toxicity With Docetaxel, No Apparent Benefit of Zoledronic Acid in Prostate Cancer
As reported in The Lancet by James et al, results of the STAMPEDE trial, which used a multiarm, multistage seamless phase II/III design, showed increased survival and toxicity with docetaxel and little benefit of zoledronic acid when added to first-line long-term hormone therapy in patients with...
